KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $12.5 million.

  • AbCellera Biologics' Depreciation & Amortization (CF) rose 13.16% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 7.06%. This contributed to the annual value of $12.5 million for FY2024, which is 2.05% down from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Depreciation & Amortization (CF) is $12.5 million, which was down 2.05% from $12.8 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Depreciation & Amortization (CF) registered a high of $12.8 million during FY2023, and its lowest value of $2.3 million during FY2020.
  • In the last 3 years, AbCellera Biologics' Depreciation & Amortization (CF) had a median value of $12.5 million in 2024 and averaged $11.4 million.
  • In the last 5 years, AbCellera Biologics' Depreciation & Amortization (CF) soared by 104.41% in 2022 and then decreased by 2.05% in 2024.
  • AbCellera Biologics' Depreciation & Amortization (CF) (Yearly) stood at $2.3 million in 2020, then soared by 90.03% to $4.4 million in 2021, then spiked by 104.41% to $9.0 million in 2022, then skyrocketed by 42.22% to $12.8 million in 2023, then decreased by 2.05% to $12.5 million in 2024.